Literature DB >> 1358582

Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine.

L Naesens1, J Balzarini, E De Clercq.   

Abstract

The pharmacokinetics of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent inhibitor of retrovirus (i.e. human immunodeficiency virus) replication was determined in mice. Upon iv bolus administration of PMEA at 25, 100, or 500 mg/kg, PMEA was rapidly cleared from the plasma in a monoexponential and dose-independent manner (half-life, 7-12.5 min; distribution volume, 0.30-0.36 liter/kg; total body clearance, 1.21-2.41 liters/hr/kg). Irrespective of the initial PMEA dose, 67% of unchanged PMEA was recovered from the urine of mice within 24 hr after administration of PMEA. [3H]PMEA, administered as an iv bolus injection, mainly accumulated in the kidney, liver, and lungs. Significant amounts of monophosphorylated PMEA were detected in kidney and liver, but not other tissues, at 10, 30, and 60 min after iv administration of PMEA. Low but significant levels of PMEA were attained in the brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358582

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  Cryopreservation enables long-term storage of 9-(2-phosphonylmethoxyethyl)adenine prodrug-loaded reconstituted lactosylated high-density lipoprotein.

Authors:  R L de Vrueh; T J van Berkel; M K Bijsterbosch
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 2.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

Review 3.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

4.  Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.

Authors:  R L de Vrueh; E T Rump; E van De Bilt; R van Veghel; J Balzarini; E A Biessen; T J van Berkel; M K Bijsterbosch
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Disposition of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.

Authors:  M K Bijsterbosch; L J Smeijsters; T J van Berkel
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

7.  Na⁺/H⁺ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney.

Authors:  Joonhee Park; Jin-Oh Kwak; Brigitte Riederer; Ursula Seidler; Susan P C Cole; Hwa Jeong Lee; Min Goo Lee
Journal:  J Am Soc Nephrol       Date:  2014-01-16       Impact factor: 10.121

8.  Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys.

Authors:  K C Cundy; J P Shaw; W A Lee
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo.

Authors:  J Neyts; F Stals; C Bruggeman; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.